查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2075067

伴侶動物癌症篩檢市場預測至2034年—按檢測類型、癌症類型、技術、最終用戶和地區分類的全球分析

Companion Animal Cancer Screening Market Forecasts to 2034 - Global Analysis By Test Type (Liquid Biopsy, Tissue Biopsy, Genomic Testing, Biomarker Tests and Heat Diffusion Imaging), Cancer Type, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球伴侶動物癌症篩檢市場規模將達到 6 億美元，並在預測期內以 13.0% 的複合年成長率成長，到 2034 年將達到 16 億美元。

伴侶動物癌症篩檢是指系統性地運用診斷測試和評估方法，在寵物（主要是犬貓）出現臨床症狀之前，檢測出癌症或癌前病變。這包括評估生物檢體、影像學結果、基因標記和其他健康指標，以確定是否有惡性疾病、風險或處於早期階段。伴侶動物癌症篩檢的目標是實現早期診斷，支持及時治療性介入，並改善寵物的整體健康和生活品質。

伴侶動物癌症發生率上升

伴侶動物（尤其是犬貓）癌症發生率的不斷上升，推動了獸醫腫瘤學領域對先進篩檢技術的持續需求。流行病學研究估計，四分之一的犬隻在一生中會患有某種腫瘤性疾病，這意味著需要篩檢的動物數量龐大且持續不斷。獸醫學的進步延長了伴侶動物的壽命，但也增加了老年動物罹患腫瘤性疾病的風險。針對飼主主人的獸醫健康意識宣傳活動正在推動將定期癌症篩檢納入預防保健，從而提高了篩檢頻率，不再局限於出現症狀後才進行篩檢。

保險報銷限額有限

寵物保險政策中缺乏伴侶動物癌症篩檢的標準化報銷框架，大大限制了這些檢測的普及率。大多數寵物保險計劃將晚期癌症診斷歸類為“可選項目”，從而限制了報銷範圍。全面的基因組檢測和液態生物檢體項目的自付費用從數百美元到數千美元不等，這給擔心費用的寵物飼主造成了經濟障礙。當獸醫建議對無症狀動物篩檢時，由於即時無法看到明顯的臨床效益，往往會遭到寵物飼主的抵制。因此，證明其成本效益是擴大保險覆蓋範圍的先決條件。

液態生物檢體的商業化

獸醫液態生物檢體平台的商業化為伴侶動物癌症篩檢的廣泛應用帶來了突破性的機會。基於血液的循環腫瘤DNA檢測無需進行侵入性組織取樣，顯著降低了獸醫和飼主進行檢測的門檻。 PetDx的「OncoK9」平台已通過概念驗證（PoC）實現了僅需單次血液樣本即可早期檢測犬類多種癌症。定序成本的降低和生物資訊分析工具的改進正在提高循環DNA檢測的靈敏度和特異性。 PetDx在獸醫液態生物檢體領域的先鋒地位為其在這個快速商業化但仍處於早期發展階段的領域提供了永續的競爭優勢。

監管管道的不確定性

針對伴侶動物體外診斷醫療設備的監管環境不斷變化，這給開發篩檢篩檢測試的公司帶來了商業化風險。美國食品藥物管理局(FDA) 和國際監管機構尚未針對獸醫領域的伴侶動物癌症篩檢測試制定明確的核准流程。缺乏標準化的分析驗證要求，給尋求進入監管市場的製造商帶來了不確定性。不同驗證調查方法的競爭平台的存在，也使得比較證據的取得變得更加複雜。法規核准的延遲可能會使產品上市時間延長數年，從而限制早期診斷公司研發投資的回報。

新型冠狀病毒（COVID-19）的影響

新冠疫情期間，由於動物醫院優先處理急診病例，並減少了選擇性診斷程序，獸醫腫瘤服務受到衝擊。實驗室也面臨專業分子診斷劑短缺的問題。然而，疫情期間寵物領養數量的激增導致伴侶動物總數永久性增加，擴大了長期檢查室的基數。隨著疫情後的復甦，就診量下降，先前被延後的診斷需求也逐漸顯現。疫情期間，寵物飼主對寵物投入的情感也顯著增加，這從根本上提高了他們對高預防性篩檢的投入意願。

在預測期內，液態生物檢體領域預計將佔據最大的市場佔有率。

由於其非侵入性的檢體採集能力以及僅需一份血液樣本即可早期檢測多種癌症的能力，液態生物檢體預計將在預測期內佔據最大的市場佔有率。液態生物檢體平台作為一種第一線篩檢工具，正迅速受到獸醫腫瘤學家的青睞，因為它避免了麻醉和組織取樣相關的風險。在臨床症狀出現之前檢測循環腫瘤DNA的能力，與獸醫專業組織日益倡導的預防醫學理念不謀而合。 PetDx和VolitionRx Limited的商業平台正在建立臨床有效的資料庫，這將加速液體活體組織切片技術在醫療機構中的應用。

預計在預測期內，淋巴瘤細分市場將呈現最高的複合年成長率。

在預測期內，淋巴瘤細分市場預計將呈現最高的成長率，這主要受犬貓淋巴瘤發病率上升以及人們對早期癌症檢測日益重視的推動。寵物飼主對癌症症狀和預防保健意識的提高，促進了篩檢檢測的普及。液態生物檢體技術、分子診斷和獸醫腫瘤學的進步提高了診斷的準確性。此外，寵物就診量的增加以及獲得專業癌症治療服務的管道擴大，預計也將加速該細分市場的成長。

市佔率最大的地區

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其獸醫腫瘤專家的高度集中、先進的診斷檢測設施完善的基礎設施以及全球最商業性的寵物保險市場。美國擁有體液切片檢查和基因組檢測領域的先驅企業，例如 PetDx、OncoK9 和 Antech Diagnostics。機構對獸醫學的投資正在推動臨床檢驗研究活動。飼主越來越願意為寵物投入全面的癌症治療，這也促進了先進診斷方法的應用。

複合年成長率最高的地區

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於日本、韓國、澳洲和中國獸醫腫瘤基礎設施的快速擴張，以及老年寵物飼主對癌症預防篩檢意識的不斷提高。日本和韓國政府資助的獸醫研究舉措已納入伴侶動物腫瘤生物標記研究。澳洲和日本寵物保險普及率的提高，正在增強先進診斷測試的保險報銷機制。該地區不斷擴大的專科獸醫醫院網路，也帶動了對參考實驗室癌症篩檢服務的機構需求。

免費客製化服務

所有購買此報告的客戶均可享受以下免費自訂選項之一。

  • 企業概況
    • 對其他市場參與企業進行全面分析（最多 3 家公司）
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 透過產品系列、地域覆蓋和策略聯盟對標領先企業。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 成長機會和重點投資領域
  • 工業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球伴侶動物癌症篩檢市場：依檢測類型分類

  • 液態生物檢體
  • 組織切片檢查
  • 基因組檢測
  • 生物標記檢測
  • 熱擴散成像

第6章 全球伴侶動物癌症篩檢市場：依癌症類型分類

  • 淋巴瘤
  • 肥大細胞瘤
  • 骨癌
  • 血管肉瘤
  • 皮膚和皮下腫塊
  • 乳腺腫瘤

第7章 全球伴侶動物癌症篩檢市場：依技術分類

  • 下一代定序
  • 聚合酵素鏈鎖反應
  • 免疫組織化學
  • 流式細胞技術
  • 原位雜合
  • 人工智慧影像分析

第8章 全球伴侶動物癌症篩檢市場：以最終用戶分類

  • 動物醫院
  • 動物診所
  • 診斷實驗室
  • 學術研究機構
  • 寵物飼主

第9章 全球伴侶動物癌症篩檢市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 其他
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲地區

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • IDEXX Laboratories Inc.
  • Zoetis Inc.
  • PetDx
  • VolitionRx Limited
  • OncoK9
  • HT VET
  • Antech Diagnostics
  • Heska Corporation
  • Mars Petcare
  • Thermo Fisher Scientific Inc.
  • BioMerieux SA
  • Neogen Corporation
  • Randox Laboratories Ltd.
  • Labcorp
  • QIAGEN NV
  • Danaher Corporation
Product Code: SMRC37528

According to Stratistics MRC, the Global Companion Animal Cancer Screening Market is accounted for $0.6 billion in 2026 and is expected to reach $1.6 billion by 2034 growing at a CAGR of 13.0% during the forecast period. Companion Animal Cancer Screening refers to the systematic use of diagnostic tests and assessment methods to detect cancer or precancerous conditions in pets, primarily dogs and cats, before clinical symptoms become evident. It involves evaluating biological samples, imaging results, genetic markers, or other health indicators to identify the presence, risk, or early development of malignant diseases. The objective of companion animal cancer screening is to enable earlier diagnosis, support timely therapeutic intervention, and improve overall health outcomes and quality of life.

Market Dynamics:

Driver:

Rising companion animal cancer prevalence

The increasing incidence of cancer in companion animals, particularly dogs and cats, is driving sustained demand for advanced screening technologies in veterinary oncology. Epidemiological studies estimate that one in four dogs will develop a neoplastic condition during their lifetime, establishing a substantial and recurring testing population. Advances in veterinary medicine that extend companion animal lifespans have expanded the proportion of aging animals susceptible to oncological conditions. Owner awareness campaigns by veterinary associations are normalizing routine cancer screening as a preventive care component, expanding testing frequency beyond symptomatic presentations.

Restraint:

Limited reimbursement frameworks

The absence of standardized reimbursement frameworks for companion animal cancer screening within pet insurance policies significantly constrains testing adoption rates. Most pet insurance plans categorize advanced oncology diagnostics as elective procedures, limiting reimbursement eligibility. Out-of-pocket costs for comprehensive genomic or liquid biopsy panels range from several hundred to several thousand dollars, creating price sensitivity barriers among cost-conscious pet owners. Veterinary practitioners face client resistance when recommending screening tests for asymptomatic animals where immediate clinical benefit is non-obvious. Establishing cost-effectiveness evidence is a prerequisite for broader insurance coverage inclusion.

Opportunity:

Liquid biopsy commercialization

The commercial launch of veterinary liquid biopsy platforms represents a transformative opportunity for companion animal cancer screening adoption. Blood-based circulating tumor DNA tests eliminate the need for invasive tissue sampling, significantly reducing procedure-related barriers for both practitioners and pet owners. PetDx's OncoK9 platform has demonstrated proof-of-concept for multi-cancer early detection in dogs through a single blood draw. Declining sequencing costs and improving bioinformatic analysis tools are expanding the sensitivity and specificity of circulating DNA detection panels. First-mover positioning in veterinary liquid biopsy generates a sustainable competitive advantage in a nascent but rapidly commercializing segment.

Threat:

Regulatory pathway uncertainties

The evolving regulatory landscape for companion animal in vitro diagnostic devices introduces commercialization risk for cancer screening test developers. The United States Food and Drug Administration and international regulatory bodies have not yet established clear approval pathways specifically for veterinary companion animal cancer screening assays. Absence of standardized analytical validation requirements creates uncertainty for manufacturers seeking regulated market access. Competing platforms with divergent validation methodologies complicate comparative evidence generation. Regulatory delays can extend time-to-market by multiple years, constraining return on research and development investment for early-stage diagnostic companies.

Covid-19 Impact:

The COVID-19 pandemic disrupted veterinary oncology services as clinics prioritized urgent care and reduced elective diagnostic procedures during lockdown periods. Laboratory supply chains for specialized molecular diagnostic reagents experienced material shortages. However, pandemic-period pet adoption surges permanently enlarged the companion animal population, expanding the long-term testing addressable base. Post-pandemic recovery accelerated veterinary visit frequency backlogs, generating deferred diagnostic demand. Increased owner emotional investment in pandemic-era pets has structurally raised willingness to invest in advanced preventive screening.

The liquid biopsy segment is expected to be the largest during the forecast period

The liquid biopsy segment is expected to account for the largest market share during the forecast period, due to its non-invasive sampling requirements and capacity for multi-cancer early detection from a single blood draw. Liquid biopsy platforms are gaining rapid adoption among veterinary oncologists as a first-line screening tool that avoids the anesthetic and procedural risks associated with tissue sampling. The ability to detect circulating tumor DNA before clinical signs manifest aligns with preventive care frameworks increasingly advocated by veterinary professional bodies. Commercial platforms from PetDx and VolitionRx Limited are establishing clinical validity databases that accelerate institutional adoption.

The lymphoma segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the lymphoma segment is predicted to witness the highest growth rate, driven by the increasing prevalence of lymphoma among dogs and cats and the growing emphasis on early cancer detection. Rising awareness among pet owners regarding cancer symptoms and preventive healthcare is supporting greater adoption of screening tests. Advances in liquid biopsy technologies, molecular diagnostics, and veterinary oncology are enhancing diagnostic accuracy. Additionally, increasing veterinary visits and expanding access to specialized cancer care services are expected to accelerate growth in this segment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the highest concentration of veterinary oncology specialists, advanced diagnostic laboratory infrastructure, and the most commercially mature pet insurance market globally. The United States hosts pioneering liquid biopsy and genomic testing companies including PetDx, OncoK9, and Antech Diagnostics. Institutional investment from academic veterinary schools drives clinical validation study activity. Strong owner willingness to invest in comprehensive cancer care for companion animals sustains premium diagnostic adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding veterinary oncology infrastructure in Japan, South Korea, Australia, and China and rising owner awareness of preventive cancer screening in aging pet populations. Government-funded veterinary research initiatives in Japan and South Korea incorporate companion animal oncology biomarker programs. Growing pet insurance penetration in Australia and Japan improves reimbursement pathways for advanced diagnostic testing. The region's expanding network of specialty veterinary hospitals is creating institutional demand for reference laboratory cancer screening services.

Key players in the market

Some of the key players in Companion Animal Cancer Screening Market include IDEXX Laboratories Inc., Zoetis Inc., PetDx, VolitionRx Limited, OncoK9, HT VET, Antech Diagnostics, Heska Corporation, Mars Petcare, Thermo Fisher Scientific Inc., BioMerieux SA, Neogen Corporation, Randox Laboratories Ltd., Labcorp, QIAGEN N.V., and Danaher Corporation.

Key Developments:

In June 2026, IDEXX Laboratories Inc. launched an expanded companion animal multi-cancer early detection panel incorporating circulating tumor DNA analysis across 14 cancer types, available through its global reference laboratory network with 72-hour reporting turnaround.

In May 2026, PetDx published peer-reviewed clinical validation data demonstrating 85 percent sensitivity for early-stage lymphoma detection in dogs using its OncoK9 liquid biopsy platform, significantly advancing evidence for routine preventive screening adoption.

In March 2026, Zoetis Inc. announced a strategic collaboration with a leading academic veterinary oncology center to co-develop a feline cancer genomic biomarker panel targeting mammary tumors and lymphoma for commercial launch in 2027.

Test Types Covered:

  • Liquid Biopsy
  • Tissue Biopsy
  • Genomic Testing
  • Biomarker Tests
  • Heat Diffusion Imaging

Cancer Types Covered:

  • Lymphoma
  • Mast Cell Tumors
  • Osteosarcoma
  • Hemangiosarcoma
  • Dermal and Subcutaneous Masses
  • Mammary Tumors

Technologies Covered:

  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Immunohistochemistry
  • Flow Cytometry
  • In Situ Hybridization
  • AI-Based Image Analysis

End Users Covered:

  • Veterinary Hospitals
  • Veterinary Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Pet Owners

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Companion Animal Cancer Screening Market, By Test Type

  • 5.1 Liquid Biopsy
  • 5.2 Tissue Biopsy
  • 5.3 Genomic Testing
  • 5.4 Biomarker Tests
  • 5.5 Heat Diffusion Imaging

6 Global Companion Animal Cancer Screening Market, By Cancer Type

  • 6.1 Lymphoma
  • 6.2 Mast Cell Tumors
  • 6.3 Osteosarcoma
  • 6.4 Hemangiosarcoma
  • 6.5 Dermal and Subcutaneous Masses
  • 6.6 Mammary Tumors

7 Global Companion Animal Cancer Screening Market, By Technology

  • 7.1 Next-Generation Sequencing
  • 7.2 Polymerase Chain Reaction
  • 7.3 Immunohistochemistry
  • 7.4 Flow Cytometry
  • 7.5 In Situ Hybridization
  • 7.6 AI-Based Image Analysis

8 Global Companion Animal Cancer Screening Market, By End User

  • 8.1 Veterinary Hospitals
  • 8.2 Veterinary Clinics
  • 8.3 Diagnostic Laboratories
  • 8.4 Academic and Research Institutes
  • 8.5 Pet Owners

9 Global Companion Animal Cancer Screening Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 IDEXX Laboratories Inc.
  • 12.2 Zoetis Inc.
  • 12.3 PetDx
  • 12.4 VolitionRx Limited
  • 12.5 OncoK9
  • 12.6 HT VET
  • 12.7 Antech Diagnostics
  • 12.8 Heska Corporation
  • 12.9 Mars Petcare
  • 12.10 Thermo Fisher Scientific Inc.
  • 12.11 BioMerieux SA
  • 12.12 Neogen Corporation
  • 12.13 Randox Laboratories Ltd.
  • 12.14 Labcorp
  • 12.15 QIAGEN N.V.
  • 12.16 Danaher Corporation

List of Tables

  • Table 1 Global Companion Animal Cancer Screening Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Companion Animal Cancer Screening Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 3 Global Companion Animal Cancer Screening Market Outlook, By Liquid Biopsy (2023-2034) ($MN)
  • Table 4 Global Companion Animal Cancer Screening Market Outlook, By Tissue Biopsy (2023-2034) ($MN)
  • Table 5 Global Companion Animal Cancer Screening Market Outlook, By Genomic Testing (2023-2034) ($MN)
  • Table 6 Global Companion Animal Cancer Screening Market Outlook, By Biomarker Tests (2023-2034) ($MN)
  • Table 7 Global Companion Animal Cancer Screening Market Outlook, By Heat Diffusion Imaging (2023-2034) ($MN)
  • Table 8 Global Companion Animal Cancer Screening Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 9 Global Companion Animal Cancer Screening Market Outlook, By Lymphoma (2023-2034) ($MN)
  • Table 10 Global Companion Animal Cancer Screening Market Outlook, By Mast Cell Tumors (2023-2034) ($MN)
  • Table 11 Global Companion Animal Cancer Screening Market Outlook, By Osteosarcoma (2023-2034) ($MN)
  • Table 12 Global Companion Animal Cancer Screening Market Outlook, By Hemangiosarcoma (2023-2034) ($MN)
  • Table 13 Global Companion Animal Cancer Screening Market Outlook, By Dermal and Subcutaneous Masses (2023-2034) ($MN)
  • Table 14 Global Companion Animal Cancer Screening Market Outlook, By Mammary Tumors (2023-2034) ($MN)
  • Table 15 Global Companion Animal Cancer Screening Market Outlook, By Technology (2023-2034) ($MN)
  • Table 16 Global Companion Animal Cancer Screening Market Outlook, By Next-Generation Sequencing (2023-2034) ($MN)
  • Table 17 Global Companion Animal Cancer Screening Market Outlook, By Polymerase Chain Reaction (2023-2034) ($MN)
  • Table 18 Global Companion Animal Cancer Screening Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 19 Global Companion Animal Cancer Screening Market Outlook, By Flow Cytometry (2023-2034) ($MN)
  • Table 20 Global Companion Animal Cancer Screening Market Outlook, By In Situ Hybridization (2023-2034) ($MN)
  • Table 21 Global Companion Animal Cancer Screening Market Outlook, By AI-Based Image Analysis (2023-2034) ($MN)
  • Table 22 Global Companion Animal Cancer Screening Market Outlook, By End User (2023-2034) ($MN)
  • Table 23 Global Companion Animal Cancer Screening Market Outlook, By Veterinary Hospitals (2023-2034) ($MN)
  • Table 24 Global Companion Animal Cancer Screening Market Outlook, By Veterinary Clinics (2023-2034) ($MN)
  • Table 25 Global Companion Animal Cancer Screening Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 26 Global Companion Animal Cancer Screening Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 27 Global Companion Animal Cancer Screening Market Outlook, By Pet Owners (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.